Last reviewed · How we verify
CPX-351 in cohort B
At a glance
| Generic name | CPX-351 in cohort B |
|---|---|
| Sponsor | Groupe Francophone des Myelodysplasies |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat (PHASE1, PHASE2)
- CPX-351+GO in Subjects 55 Years Old, or Older, With AML (PHASE1)
- CPX-351 in Higher Risk Myelodysplastic Syndromes (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CPX-351 in cohort B CI brief — competitive landscape report
- CPX-351 in cohort B updates RSS · CI watch RSS
- Groupe Francophone des Myelodysplasies portfolio CI